Labcorp Holdings stock
LHNYSELabcorp Holdings Inc., HealthcareISIN US5049221055
64Score 64 out of 100, Neutral
Price and trend
82 / 100
Price history
+39% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is at its 52-week high. Largest decline in 20 years: 47% (February 2020 to March 2020).
Chart figures for advanced users
- SMA 50$328.04
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$291.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$250.39
- The lowest closing price of the last twelve months.
- Resistance$372.23
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Labcorp Holdings Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $30.23B, is number 11 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $13.95B (up 7.2% year on year) and earnings of $876.5M (up 17.5%).
- For fiscal 2026, analysts expect on average revenue of $14.83B (up 6.3%) and adjusted earnings per share of $18.51 (up 12.6%).
Show more
- MEQIRI Score 64 out of 100 (Neutral): rank 229 of 714 in Healthcare, median 53.
- The P/E is 30.3 (Medical (Diagnostics & Research) median 33.7, own median of recent years 14.9).
- Our model puts fair value at $385.26, with the price 3% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 14% since 2020.Capital allocation 68
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 87
- Earnings turn into cashFree cash flow 128% of earnings over the last 12 months.Fundamentals 87
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and fundamentals, while valuation and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 65 to 64.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $321.05 and expensive above $481.58 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $355.39 (cash-flow model) and $415.13 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.9%. At 10.9% the fair value would be $358.82, at 8.9% it would be $422.19.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 4.1% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 27%, operating 11%, net 6%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 16 Feb 2027in 96 days
- Last reported
- 28 Oct 2026EPS reported $4.78 (expected $4.64)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $18.51+0.8%
- Revenue
- $14.83B+0.5%
- Earnings per share
- $19.74−0.5%
- Revenue
- $15.64B+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +11.2%Labcorp raised its 2026 guidance, lifting the revenue midpoint by $65 million and adjusted EPS midpoint by $0.18, with BLS segment revenue growth now expected at 7.4% to 8.4%, up from the prior range.
“As a result, we are raising the midpoint of our 2026 enterprise revenue range and adjusted EPS range by $65 million and $0.18, respectively.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $4.71M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Caveney Brian JSale
10 Nov 2026, EVP, Pres of BLS, CMO & CSO
- Shares
- 2,000
- Price
- $372.04
- Value
- $744,080
- Vaughn Bryan TSale
3 Nov 2026, EVP and President, Diagnostics
- Shares
- 306
- Price
- $353.70
- Value
- $108,232
- Parham Richelle PSale
30 Oct 2026, Board
- Shares
- 1,078
- Price
- $361.22
- Value
- $389,395
Show 7 more
- Anderson Kerrii BSale
17 Aug 2026, Board
- Shares
- 3,000
- Price
- $318.02
- Value
- $954,060
- Schechter Adam HSale
11 Aug 2026, President & CEO
- Shares
- 4,669
- Price
- $320.37
- Value
- $1.5M
- Summy Amy B.Sale
4 Aug 2026, EVP, Chief Marketing Officer
- Shares
- 924
- Price
- $306.74
- Value
- $283,428
- Wilkinson Peter JSale
3 Aug 2026, SVP, Chief Accounting Officer
- Shares
- 1,420
- Price
- $309.23
- Value
- $439,107
- Kyle Kathryn WSale
2 Jul 2026, EVP, Chief Legal Officer
- Shares
- 92
- Price
- $286.19
- Value
- $26,329
- Vaughn Bryan TSale
2 Jul 2026, EVP and President, Diagnostics
- Shares
- 234
- Price
- $286.19
- Value
- $66,968
- Kyle Kathryn WSale
8 Jun 2026, EVP, Chief Legal Officer
- Shares
- 762
- Price
- $263.89
- Value
- $201,084
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Labcorp Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 64
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- WatersWAT $46.24B56
- IQVIA HoldingsIQV $45.24B67
- Mettler-Toledo InternationalMTD $35.04B76
- IlluminaILMN $32.2B70
- Quest DiagnosticsDGX $28.55B69
- Guardant HealthGH $20.94B45
- Medpace HoldingsMEDP $18.59B83
- RevvityRVTY $17.66B56
ETFs that hold Labcorp Holdings
Held by 126 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 4.24% | 0.68% | €5.31M |
| State Street SPDR S&P 500 Low Volatility UCITS ETF (Acc)SPY1 | 0.96% | 0.35% | €106.3M |
| UBS Factor MSCI USA Low Volatility UCITS ETF hEUR accUBUV | 0.87% | 0.21% | €64.75M |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.66% | 0.40% | €807M |
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.48% | 0.20% | €268.74M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.44% | 0.15% | €592.11M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.44% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.43% | 0.15% | €3.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jun 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.